Darzalex fails futility analysis in NHL study

Following a futility assessment, Genmab A/S (CSE:GEN) said that its partner, the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ), will not advance Darzalex daratumumab into the second stage of the Phase II CARINA trial to treat relapsed or refractory non-Hodgkin’s lymphoma.

The trial was intended to test Darzalex in up to 210 patients with relapsed or refractory follicular lymphoma, diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Genmab said Darzalex monotherapy did not reach the overall response rate (ORR) futility threshold in either the follicular lymphoma or DLBCL cohorts. ORR was not evaluable in the MCL cohort due to slow recruitment...